Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Magnetic imaging agent (e.g., NMR, MRI, MRS, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424900100 - IN VIVO DIAGNOSIS OR IN VIVO TESTING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424900320 Particle containing a transition, actinide, or lanthanide metal (e.g., hollow or solid particle, granule, etc.) 136
424900360 Transition, actinide, or lanthanide metal containing 67
424900340 Polypeptide attached to or complexed with the agent (e.g., protein, antibody, etc.) 56
424900350 Carbohydrate or derivative thereof attached to or complexed with the agent 20
424900370 Imageable halogen containing 14
424900330 Nitroxide or nitroxide containing 6
Entries
DocumentTitleDate
20090311190SELF-ASSEMBLED, MICROPATTERNED, AND RADIO FREQUENCY (RF) SHIELDED BIOCONTAINERS AND THEIR USES FOR REMOTE SPATIALLY CONTROLLED CHEMICAL DELIVERY - The present invention relates to a nanoscale or microscale particle for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the particle, with subsequent release of the therapeutic materials in situ, methods of fabricating the particle by folding a 2D precursor into the 3D particle, and the use of the particle in in-vivo or in-vitro applications The particle can be in any polyhedral shape and its surfaces can have either no perforations or nano/microscale perforations The particle is coated with a biocompatible metal, e g gold, or polymer e g parvlene, layer and the surfaces and hinges of the particle are made of any metal or polymer combinations.12-17-2009
20110177002CYLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE - The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a reporting tag like fluorescein or a radioisotope including substituent.07-21-2011
20090068112Magnetic Nanoparticles for Imaging - A medical imaging system that enables the discovery of malignant tissue utilizing contrast agents and heating agents made of magnetic nanoparticles that are delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites is disclosed. The thermal contrast agents may be temperature self-controlled magnetic nanoparticles that may be encapsulated in a biocompatible coating. The thermal contrast agents may be uploaded into attenuated strains of bacteria that seek and reside in tumor tissue when placed into a bloodstream of a patient. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient, and a thermal scan may be utilized to identify tumors. In another embodiment, the contrast agent may be formed from magnetic nanoparticles having distinct magnetic moment profiles, and a MRI system may be utilized to identify tumors with such contrast agent.03-12-2009
20090196826COMPOSITIONS AND METHODS OF MAKING NON-SPHERICAL MICRO- AND NANO-PARTICLES - The present invention includes compositions, methods and pharmaceutical compositions formed by template-directed polymer molding by contacting a porous template with one or more layers of polymeric material coated on a release layer coated on a substrate, applying pressure to the porous template, the substrates or both and separating the porous template from the polymer material to form one or more polymer nonspherical nanostructures with one or more layers on the substrate. The template includes one or more nonspherical nanostructure features. The size and shape of the one or more single- or multi-layer polymeric nonspherical nanostructures are controlled by the one or more nonspherical nanostructure features and the polymer material optionally including one or more active agents with or without retardants, dyes, etc.08-06-2009
20110189100BONE SUBSTITUTE CONTAINING A CONTRAST AGENT, METHOD FOR PREPARING SAME AND USES THEREOF - The invention relates to a composition for biomaterials, characterised in that it comprises a calcium phosphate, in which the molar ratio Ca/P is 1 to 2, sintered with a medical imaging contrast agent uniformly distributed in the composition mass. The invention also relates to a method for preparing the same and to the medical uses thereof.08-04-2011
20090060841APPARATUS AND METHOD FOR COMBINED USE OF VARIABLE FLIP ANGLES AND CENTRIC PHASE ENCODING IN HYPERPOLARIZED 13C IMAGING - A system and method for MR imaging includes a magnetic resonance imaging (MRI) system having a plurality of gradient coils positioned about a bore of a magnet, and an RF transceiver system and an RF switch controlled by a pulse module to transmit RF signals to an RF coil assembly to acquire MR images. The apparatus further includes a controller programmed to determine a variable flip angle (VFA) sequence to excite a hyperpolarized material in a subject and to determine a delay period during which application of the VFA sequence is delayed after injection of a hyperpolarized contrast agent. The delay period is based on dynamic data of the hyperpolarized material acquired from the subject. The controller is also programmed to cause application of the VFA sequence to excite the hyperpolarized material in the subject and to acquire MR data from the hyperpolarized material using an isotropic centric phase encoding (iCPE) technique.03-05-2009
20100086488HYDROPHILIC NANOPARTICLES WITH FUNCTIONAL SURFACE GROUPS, PRODUCTION AND USE THEREOF - The present invention relates to nanoparticles having a hydrophilic surface coating, to methods of production thereof and to the use thereof in biological, molecular biological, biochemical and medical applications.04-08-2010
20110195028MAGNETIC RESONANCE IMAGING AND/OR SPECTROSCOPY CONTRAST AGENTS AND METHODS OF USE THEREOF - The presently disclosed subject matter demonstrates that a spin state which has zero magnetic resonance signal, but an extremely long lifetime, can be used to store magnetization, which can then be recovered into an observable transition. Coupled with hyper-polarization techniques, this permits the preparation of a wide range of contrast agent molecules for use in magnetic resonance imaging (MRI) techniques that have long effective relaxation time.08-11-2011
20110195027CD9-SPECIFIC HUMAN ANTIBODIES - The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.08-11-2011
20100034747Detection of HIV-1 Infection - This invention provides methods for to the use of the difference in phosphodiester (PDE)/phosphomonoester (PME) ratio in biological fluids, as an analytical criterion to image both the presence and degree of viral infection in-vivo.02-11-2010
20130084246METHOD AND SYSTEM FOR QUANTITATIVE RENAL ASSESSMENT - Method and system embodiments of the present invention employ computational analysis tools running on one or more computer systems to quantitatively analyze MRI data from patients in order to both assess various functional parameters and characteristics of a patient's kidney, as well as to provide an electronic display device interconnected with the one or more computer systems, and accessible visualization of the quantitative assessment to facilitate diagnosis of various types of kidney abnormalities and pathologies.04-04-2013
20090016964HYPERPOLARIZATION METHODS, SYSTEMS AND COMPOSITIONS - The invention provides various methods and systems for providing hyperpolarized materials as well as the hyperpolarized materials so provided. In addition, a method of providing hyperpolarized materials, such as agents, to end users from a remote location is also provided.01-15-2009
20130039858NIR MATERIALS AND NANOMATERIALS FOR THERANOSTIC APPLICATIONS - Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and in other embodiments of the invention a dye is coordinate or ionic bound within the metal oxide matrix. A method for preparing the novel covalently bondable modified fluorescent dyes is presented. A method to prepare silica comprising nanoparticles that are 3 to 8 nm in diameter is presented. In some embodiments, the fluorescent dye comprising metal oxide nanoparticles are further decorated with functionality for use as multimodal in vitro or in vivo imaging agents. In other embodiments of the invention, the fluorescent dye comprising metal oxide nanoparticles provide therapeutic activity and incorporated therapeutic temperature monitoring.02-14-2013
20100104514NANOPARTICLE CLUSTERS AND METHODS FOR FORMING SAME - A method for providing nanoparticle clusters of controlled dimensions is described. The method involves an activation of individual nanoparticles and the subsequent interaction between activated particles to form a cluster.04-29-2010
20090155181Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents - The invention relates to compositions comprising a gadolinium-based contrast agent and a derivatized cyclodextrin. Further provided are methods for reducing the toxicity associated with gadolinium-based contrast agents.06-18-2009
20100092390Methods for Making Particles Having Long Spin-Lattice Relaxation Times - Methods for making collections of small particles having spin-lattice relaxation times greater than about 5 minutes are described. The long-T04-15-2010
20080260646Imaging Reporters of Transgene Expression - Disclosed are compositions and methods for imaging in animals.10-23-2008
20090092554ENCAPSULATED CONTRAST AGENTS - The present invention relates to the field of polymer chemistry and more particularly to encapsulated contrast agents and methods for using the same.04-09-2009
201300588703D NANOCRYSTALS AND MANUFACTURING METHODS - The invention relates to nanocrystals, containing one or more metals as defined in the specification; having a size of 2 to 200 nm; having a defined, three-dimensional polyhedral structure, optionally functionalized by ligands and/or embedded crystals. The invention further relates to monodisperse assemblies of such nanocrystals, to formulations and devices comprising such nanocrystals as well as to the manufacture and use thereof.03-07-2013
20130058869Prevention And Treatment Of Amyloidogenic Disease - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.03-07-2013
20110038801METHODS AND COMPOSITIONS FOR IDENTIFYING LUNG CANCER OR A HUMORAL IMMUNE RESPONSE AGAINST LUNG CANCER - Methods and compositions are provided for identifying lung cancer or a humoral immune response against lung cancer. Also disclosed are methods for determining whether a subject is responding or is likely to respond to lung cancer immunotherapy.02-17-2011
20090238764DIAGNOSTIC THERAPEUTIC METHOD - A pharmaceutical preparation containing magnetic vesicular particles is disclosed, wherein the magnetic vesicular particles each include magnetic microparticles within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a hydroxyl group, a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, a dithio group, a thiocarboxyl group and a dithiocarboxyl group is bonded to the magnetic microparticle, and the magnetic vesicular particles satisfy the following equation:09-24-2009
20090297454Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use - The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.12-03-2009
20090074671DRUG-IMMOBILIZED INORGANIC NANOPARTICLE - An object of the present invention is to provide a composite of an inorganic nanoparticle with a medicinal compound (i.e., an active substance), and to provide a method for producing the inorganic nanoparticle composite, which is highly versatile and convenient. The present invention provides an active substance-immobilized inorganic nanoparticle wherein an active substance is immobilized through physical adsorption on the surface of an inorganic nanoparticle of 1 to 500 nm in average particle size.03-19-2009
20080279777COMPOSITIONS THAT INCLUDE A HYDROPHOBIC COMPOUND AND A POLYAMINO ACID CONJUGATE - Various compositions that include a hydrophobic compound and a polyamino acid conjugate are prepared. The compositions described herein are useful for a variety of drug, biomolecule, and imaging agent delivery applications.11-13-2008
20100021388BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES - This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s).01-28-2010
20100196280FUNCTIONALIZED SOLID POLYMER NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting.08-05-2010
20100266505IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.10-21-2010
20090117048Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered.05-07-2009
20110081297Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles - The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds.04-07-2011
20080311045Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo - Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially polymersomes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprised of biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, and resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.12-18-2008
20120156139ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEROF FOR DIAGNOSING CONDITIONS AND DISORDERS - The invention relates to a neurochemical agent comprising at least one isotopically labeled carbon atom directly bonded to at least one deuterium atom, uses thereof for the manufacture of a composition for diagnosing and evaluating a condition or disease and kits comprising said agent. The invention further encompasses methods for diagnosing and evaluating a condition or disease in a subject utilizing a composition of the invention.06-21-2012
20110293528ENEMA PREPARATIONS AND THEIR USE - This invention relates to improved methods of photodynamic treatment and diagnosis of cancer and non-cancerous conditions, and in particular to improved enema preparations for use in such methods, said enema preparations comprising a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative thereof, e.g. a 5-ALA ester. Such preparations may further comprise one or more viscosity enhancing agents, mucoadhesive or mucolytic agents, penetration enhancers or chelating agents. The methods and preparations herein described are particularly suitable for use in photodynamic methods of treating and/or diagnosing cancer and non-cancerous conditions in the colon and/or rectum.12-01-2011
20110293527Modified vaccinia virus strains for use in diagnostic and therapeutic methods - Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.12-01-2011
20110171136OPTICAL IMAGING PROBES - This invention relates to optical imaging probes and the use of such probes for diagnosing and monitoring disease, and disease treatment. The optical imaging probes of the current invention can be used to identify and characterize normal and diseased tissues with regards to altered metabolic activity.07-14-2011
20080213187NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - The invention relates to novel cascade polymer complexes, to compositions comprising these compounds, to the use of the complexes in NMR diagnosis, and to processes for preparing these compounds and compositions. The complex-forming cascade polymer complexes according to the invention can be described by general formula I:09-04-2008
20110268659HIGH SHEAR APPLICATION IN DRUG DELIVERY - In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (11-03-2011
20110217241CONJUGATES OF 19F MR IMAGING TRACERS FOR USE IN MULTI-CHROMIC MRI IMAGING - Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a 09-08-2011
20090130023Multiple Contrast Agent Injection For Imaging - MRI based molecular imaging is strongly supported by the accurate quantification of contrast agents. According to an exemplary embodiment of the present invention, contrast agent is applied on the basis of a multiple injection application scheme, during which changes in relaxation rate are determined. This may provide for an accurate determination of tumor vascularity via MRI relaxometry.05-21-2009
20110171137NOVEL NANOSTRUCTURES AND PROCESS OF PREPARING SAME - A process of preparing a plurality of nanostructures, each being composed of at least one target material is disclosed. The process comprises sequentially electrodepositing a first material and the at least one target material into pores of a porous membrane having a nanometric pore diameter, to thereby obtain within the pores nanometric rods, each of the nanometric rods having a plurality of segments where any two adjacent segments are made of different materials. The process further comprises and etching the membrane and the first material, thereby obtaining the nanostructures.07-14-2011
20090142273Activatable cest MRI agent - A chemical exchange saturation transfer (CEST) contrast agent is provided. One embodiment includes a ligand and a functional group linked to the ligand. The functional group has a hydrogen exchange site and is capable of undergoing a change in chemical functionality by enzyme catalysis or reaction with a metabolite to change the chemical exchange rate or the MR frequency of the hydrogen exchange site.06-04-2009
20100119455Administering a therapeutic agent with more than one taggant - A system may include a means for administering a therapeutic agent to a subject; a means for administering a first pharmaceutically-acceptable taggant to the subject at least substantially concurrent with the therapeutic agent, the first pharmaceutically-acceptable taggant having a pharmacokinetic profile; and a means for administering a second pharmaceutically-acceptable taggant to the subject with the first pharmaceutically-acceptable taggant, the second pharmaceutically-acceptable taggant having a pharmacokinetic profile different from the pharmacokinetic profile of the first pharmaceutically-acceptable taggant.05-13-2010
20090263327MINIMALLY INVASIVE PHYSIOLOGICAL FUNCTION MONITORING AGENTS - Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.10-22-2009
20090263326NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.10-22-2009
20090285759DRUG, DRUG GUIDANCE SYSTEM, MAGNETIC DETECTION SYSTEM, AND DRUG DESIGN METHOD - A drug comprises an organic or inorganic compound, and is made magnetic by modification of side chains and/or crosslinking between side chains.11-19-2009
20090285760METHOD FOR DETECTING CANCER USING ICG FLUORESCENCE METHOD - A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion.11-19-2009
20090104123TARGETED CONTRAST AGENTS AND METHODS FOR TARGETING CONTRAST AGENTS - A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.04-23-2009
20090169480DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME - A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of07-02-2009
20090169481DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME - A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)07-02-2009
20090169479Compounds Comprising Short Aminoalcohol Chains and Metal Complexes for Medical Imgaing - The present invention relates to a compound of formula (II) chosen from (IIa) and (IIb) or of formula (VI) chosen from (VIa) and (VIb) of following general formulae:07-02-2009
20100278744PREPARATION FOR RESTENOSIS PREVENTION - The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.11-04-2010
20080213186Method of Producing a Composition, Composition and Its Use - The invention relates to a method of producing a composition comprising hyperpolarised 09-04-2008
20100290997Imaging Agents and Methods - The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional contrast agent including an MRI agent conjugated with an optical imaging agent. A method of detecting cancer is provided including injecting a dual functional contrast agent into a patient and performing both an MRI and an optical scan. The presence of the agent may indicate cancer. A method of detecting cancer by injecting PG-DTPA-Gd-NIR813 into a patient, then detecting the presence or absence of Gd in a cell or tissue of the patient and detecting the presence or absence of NIR813 in a cell or tissue of the patient is provided. The presence of Gd and NIR813 may indicate cancer.11-18-2010
20090169478In Vivo Imaging and Therapy with Magnetic Nanoparticle Conjugates - A non-invasive in vivo technique is disclosed, useful for example in detecting cancers and micrometastases. The technique may be used to selectively deliver drugs to target cells such as tumors, metastases, micrometastases, and individual malignant cells. Ligands with specificity for a target cell receptor, and optionally drug molecules as well, are covalently bound to magnetic nanoparticles, either directly or through a spacer molecule. The ligand precludes the need for a separate coating layer. For example, human breast cancer cells express receptors both for luteinizing hormone/chorionic gonadotropin (LH/CG), and for luteinizing hormone releasing hormone (LHRH). These cells can be specifically targeted by iron oxide nanoparticles covalently linked to LH/CG or LHRH. The nanoparticles are incorporated into the cancer cells through receptor-mediated endocytosis. The specific accumulation in targeted cancer cells enhances resolution for imaging, therapy, or both. The ligand may, for example, be a hormone, receptor, or antibody, or a fragment thereof.07-02-2009
20090311191IMAGING OF ATHEROSCLEROTIC PLAQUES USING LIPOSOMAL IMAGING AGENTS - Compositions and methods are disclosed for imaging atherosclerotic plaques. Example compositions comprise liposomes, the liposomes comprising: at least one first lipid or phospholipid; at least one second lipid or phospholipid which is derivatized with one or more polymers; and at least one sterically bulky excipient capable of stabilizing the liposomes. The liposomes encapsulate or associate a contrast enhancing agent.12-17-2009
20080286205Method for Treating Prostate Diseases Based on Local Delivery of Active Substances - A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.11-20-2008
20080292554Cellular Labeling for Nuclear Magnetic Resonance Techniques - The disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.11-27-2008
20080305046MOLECULAR IMAGING METHODS FOR DIAGNOSIS AND EVALUATION OF OCULAR AND SYSTEMIC DISEASES - This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners.12-11-2008
20080206146Functionalized Magnetic Nanoparticles and Methods of Use Thereof - The present invention provides functionalized magnetic nanoparticles comprising a functional group, which functionalized magnetic nanoparticles exhibit differential binding to a tissue, indulging brain tissue, bone, and vascular tissues. The present invention further provides compositions, including pharmaceutical compostions, comprising a subject functionalized magnetic nanoparticle. The present invention further provides diagnostic and research methods including use of subject functionized magnetic nanoparticles. The present invention further provides a magnetic resonance imaging (MRI)-visible drug delivery system; drugs using MRI, as well as tissue-specific drug delivery.08-28-2008
20080206145Gastro-Retentive Diagnostic Assemblies - The present invention provides a gastro-retentive diagnostic assembly (GRDA) for use in determining a condition of a subject's gastrointestinal tract (GI tract), comprising a folded single or multi-layered device comprising a diagnostic utility, such as a contrasting agent, the device prior to folding being essentially planar, and included in a delivery system for oral intake, the delivery system being adapted to release the device once in the stomach, whereupon release said device unfolds into an unfolded shape that results in the retention of the device in the stomach. Further provided are methods of determining a condition of a subject's GI tract by the use of the GRDA of the invention, as well as uses of a single or multi-layered device comprising a diagnostic utility when in a folded or unfolded shape, and method of preparing the GRDA of the invention.08-28-2008
20090180964TRANSMUCOSAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL,DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS - A method is taught that provides for transmucosal delivery of a biological cargo and optical molecular imaging probes to a subject animal or human. At least one biological cargo-laden nanoparticle imaging probe is provided in a form that will be absorbed via mucosal tissue. The biological cargo-laden nanoparticle imaging probe is delivered to the mucosal tissue of the animal or human. The method further may include steps of providing a support member adapted to receive the subject in an immobilized state; positioning the subject on the support member; and after the delivering of the imaging probe, imaging the immobilized subject using a multimodal imaging system.07-16-2009
20090180965METHODS FOR REPAIR AND REGENERATION OF BONE MARROW - The invention is directed to a method for treating a tissue or organ in a subject by directly administering an effective amount of an exogenous, decellularized extracellular matrix or a mixture of extracellular matrix and mesenchymal stem cells into the intended site of activity, such as bone marrow cavity. In one embodiment, the invention provides methods of treating bone marrow to increase the number of circulating progenitor and stem cells. In some other embodiments of the invention, the decellularized extracellular matrix to be directly administered is configured to be a time released therapeutic.07-16-2009
20090162287Method of Cardiac Imaging - The invention relates to a method of cardiac imaging using hyperpolarised 06-25-2009
20090185981METHODS AND APPARATUS FOR DYNAMICALLY ALLOCATING BANDWIDTH TO SPECTRAL, TEMPORAL, AND SPATIAL DIMENSIONS DURING A MAGNETIC RESONANCE IMAGING PROCEDURE - A system and method of dynamically allocating signal acquisition bandwidth in magnetic resonance imaging systems. The use of high spatial and high spectral resolution in MRI imaging can improve the clinical usefulness of the images. However, during uptake and washout of contrast agents, the use of high spatial and high spectral resolution results in important information being missed. Dynamic allocation of MRI signal acquisition bandwidth allows the use of high temporal resolution during contrast agent uptake and washout and high spatial and spectral resolution during periods of slower morphology resulting in images containing additional data than in conventional MRI protocols.07-23-2009
20090246140METHODS FOR IDENTIFYING AND TARGETING AUTONOMIC BRAIN REGIONS - Disclosed herein are methods for identifying and targeting autonomic and autonomic-related brain regions. In one embodiment, a method of identifying a brain region in a patient comprises administering to the patient a targeting agent that activates or inhibits a brain region and imaging the brain region.10-01-2009
20110229414Contrast Agents For Detecting Protease Activity By Means Of Hyperpolarization And For Stratifying Patients - A contrast agent is disclosed for imaging methods. In at least one embodiment the contrast agent includes a construct including i) at least two copies of a substrate for at least one tumor-specific protease, and ii) at least one linker having at least one recognition site for at least one tumor-specific protease, wherein a hyperpolarization site is located at the N and/or C terminus of the substrate, and wherein the linker is configured such that the hydrophobic ends of the substrate interact and form a central core by means of noncovalent interactions with the lipophilic residues, and the contrast agent together with a parahydrogen metal template for use in an imaging method for diagnosing a tumor. At least one embodiment of the invention further relates to a method for imaging a tumor tissue, wherein the above-described contrast agent accumulated in a tumor tissue is imaged using a suitable imaging method after hyperpolarization by way of contact with a parahydrogen metal template, and also to a method for imaging a tumor tissue in a patient, wherein a) a contrast agent as described above is administered to a patient, b) a parahydrogen metal template is administered to the patient, and c) the presence of a tumor is depicted using an imaging method.09-22-2011
20090004114System and Method for Monitoring in Vivo Drug Release Using Overhauser-Enhanced Nmr - Systems and methods for monitoring in vivo release of therapeutic and/or diagnostic agents, e.g., drugs, are provided. The disclosed systems and methods use a contrast agent and Overhauser-enhanced nuclear magnetic resonance (NMR) to monitor and/or measure the concentration and distribution of the contrast agent. Provided the contrast agent and the therapeutic/diagnostic agent have similar pharmaco-kinetics, the disclosed system/method may also be used to monitor and/or measure the concentration of such therapeutic/diagnostic agent (e.g., a drug), e.g., in the form of a volume-averaged signal and/or dynamic two-dimensional or three-dimensional images. In exemplary embodiments of the present disclosure, the therapeutic/diagnostic agent and the contrast agent are introduced to the body in an encapsulated form, e.g., within hollow nanoparticles.01-01-2009
20090220429METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS - This invention relates to a method and a system for generating a discriminatory signal for a neurological condition, where at least one probe compound that has a neurophysiologic effect is provided. Biosignal data are obtained from a subject based on biosignal measurements obtained from biosignal measuring device adapted for placement on a subject, wherein said biosignal data are obtained posterior to the administering of said probe compound to the subject. Analogous biosignal reference data are provided for reference subjects in at least one reference group posterior to the administering of the probe compound, wherein the reference data are utilized for defining reference features having common characteristics between the reference subjects in the at least one reference group, wherein the reference data are processed for defining reference posterior probability vectors for each respective reference subject, wherein each respective posterior probability vector comprises particular feature or a feature combination elements with probability values associated to said elements, the posterior probability vectors resulting in a distribution of said features or feature combinations for said reference subjects. Subsequently, the biosignal data obtained from the subject are used for calculating analogues posterior probability vector for said subject. The discriminatory signal is then generated based on comparison between said posterior probability vector for said subject and the distribution of said features or feature combinations.09-03-2009
20090117049Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered.05-07-2009
20090252686Ex Vivo Hyperpolarization of Imaging Agents - The present invention generally relates to methods for accelerating the ex vivo induction of nuclear hyperpolarization in imaging agents.10-08-2009
20090074670Hyperthermia Therapeutic Agent Delivery System - A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.03-19-2009
20090117050STEM CELL TARGETING OF CANCER, METHODS AND COMPOSITIONS THEREFOR - Disclosed are methods of detecting and treating a cancer such as an ovarian cancer using stem cells. Detection methods include administering a plurality of labeled stem cells to a subject having, or suspected of having, a cancer; and detecting the distribution of the stem cells. In some configurations, the label can be a nanoparticle such as a mono-crystalline iron oxide, which can be detected by magnetic resonance imaging. Treatment methods include administering a plurality of stem cells comprising a therapeutic agent such as an enzyme which activates a prodrug. In some configurations, the stem cells harbor a nucleic acid sequence encoding a cytosine deaminase, the cells express the enzyme, and the treatment further includes administering the prodrug 5-fluorocytosine, which is converted by the cytosine deaminase to the cytotoxic metabolite, 5-fluorouracil (5-FU).05-07-2009
20090117047Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered.05-07-2009
20100178249IMAGING MEDIUM COMPRISING LACTATE AND HYPERPOLARISED 13C-PYRUVATE - The invention relates to an imaging medium containing lactate and hyperpolarised 07-15-2010
20100254909THERMOLABILE LIPOSOME WITH A CONTROLLED RELEASE TEMPERATURE - The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.10-07-2010
2010022685913C-MR IMAGING OR SPECTROSCOPY OF CELL DEATH - The invention relates to method of 09-09-2010
20100119456Administering a therapeutic agent with more than one taggant - A system may include a means for administering a therapeutic agent to a subject; a means for administering a first pharmaceutically-acceptable taggant to the subject at least substantially concurrent with the therapeutic agent, the first pharmaceutically-acceptable taggant having a pharmacokinetic profile; and a means for administering a second pharmaceutically-acceptable taggant to the subject with the first pharmaceutically-acceptable taggant, the second pharmaceutically-acceptable taggant having a pharmacokinetic profile different from the pharmacokinetic profile of the first pharmaceutically-acceptable taggant.05-13-2010
20120141379MICROSPHERES FOR ACTIVE EMBOLIZATION - The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.06-07-2012
20100040553SPHERICAL FERRITE NANOPARTICLE AND METHOD FOR PRODUCTION THEREOF - A method for producing spherical ferrite nanoparticles includes the steps of: preparing a first aqueous solution containing a disaccharide, an alkaline, an oxidation agent, seed particles and divalent iron ions; and conducting particle growth in the first aqueous solution to produce the spherical ferrite nanoparticles.02-18-2010
20090074669PNMT as a novel marker for progenitor cells - In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders.03-19-2009
20110027189BIOCOMPATIBLE PRODUCTS FOR MAGNETIC PARTICLE IMAGING - The present invention relates to materials and methods for non-invasive imaging of biocompatible products. Biocompatible products are provided that can be visualized in vivo and in vitro using magnetic particle imaging methods. It was found that these materials can be employed for monitoring development, remodeling or degradation of biocompatible products. In another aspect, the inventive products enable substance delivery tracking and can be used to visualize targeted delivery of active agents.02-03-2011
20090110640CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICIAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS - The present invention relates to: Compounds of formula (I) consisting of a cyclic polymer core A and groups -L-X attached to said core A-(L-X)04-30-2009
20090130022MRI CONTRAST MEDIUM CONTAINING LIPOSOMES - A liposome containing a phosphatidylcholine and a phosphatidylserine in combination as membrane components at a phosphatidylcholine:phosphatidylserine molar ratio of 3:1 to 1:2, and said liposome containing superparamagnetic particles having a mean particle size not less than 1 nm and not more than 50 nm. A means for selectively accumulating an MRI contrast medium in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells such as arteriosclerosis and restenosis after PTCA is provided.05-21-2009
20130129630HYPERTHERMIA THERAPEUTIC AGENT DELIVERY SYSTEM - A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.05-23-2013
20100297022Magnetosome Gene Expression in Eukaryotic Cells - The invention is the production of magnetosome-like structures in cells. The invention provides in vitro and in vivo diagnostic and therapeutic methods using eukaryotic cells expressing magnetosome-like structures that act as contrast agents.11-25-2010
20100310467COMPOSITION AND METHOD FOR GENERATING A METABOLIC PROFILE USING 13C-MR DETECTION - The invention relates to a method of 12-09-2010
20130136696METALLIC NANOPARTICLES WITH COATED SHELLS AND APPLICATIONS OF SAME - A process or method for treating cancer. In one embodiment, the method includes the steps of providing a plurality of metallic nanoparticles, wherein each of the plurality of metallic nanoparticles has a core formed with a first metallic material, and a shell formed with a non-metallic material containing carbon, and wherein the shell is formed to enclose the metallic core completely, introducing said metallic nanoparticles into a mammal such that said metallic nanoparticles selectively target at least one type of cancerous cell, and subsequently applying at least one radio frequency of electromagnetic waves to said mammal for a period of time effective to induce skin currents in the cores of the first metallic material of said metallic nanoparticles to cause heat generated locally around targeted at least one type of cancerous cell to kill said cancerous cell.05-30-2013
20110110863COMPOSITIONS AND METHODS FOR PRODUCING EMULSIONS FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES AND OTHER APPLICATIONS - The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute05-12-2011
20110020235MR METHODS OF GRADING A TUMOR USING AN IMAGING MEDIUM THAT COMPRISES HYPERPOLARISED 13C-PYRUVATE - The invention relates to MR methods of grading a tumor using an imaging medium which comprises hyperpolarized 01-27-2011
20100254908PROCESS FOR PRODUCTION OF SURFACE-COATED INORGANIC PARTICLES - Nano-sized inorganic particles having uniform particle sizes and precisely controlled particle diameters have already been produced by synthesis in an organic solvent, but these nano-sized inorganic particles are hindered from dispersing in a polar solvent because of the adsorption of a long-chain fatty acid on the surfaces of the particles. Further, it was difficult to form nano-sized inorganic particles dispersible in a polar solvent by replacing the long-chain fatty acid coats. According to the invention, various surface-coated inorganic particles dispersible in polar solvents can be produced from fatty acid-coated inorganic particles by adding a temporary coating substance such as thiomalic acid to a nonpolar solvent containing fatty acid-coated inorganic particles dispersed therein to replace the fatty acid coats by the temporary coating substance, dispersing the inorganic particles coated with the temporary coating substance in a polar solvent, and then adding a coating substance dispersible in a polar solvent, e.g., citric acid to the obtained dispersion to replace the temporary coating substance coats covering the inorganic particles by the coating substance dispersible in a polar solvent.10-07-2010
20090214433HYPERPOLARIZED SOLID MATERIALS WITH LONG SPIN RELAXATION TIMES FOR USE AS IMAGING AGENTS IN MAGNETIC RESONANCE IMAGING - An imaging agent is disclosed for use in nuclear magnetic resonance imaging. The imaging agent includes a first substance and a second substance. The first substance includes at least one atom having non-zero nuclear spin providing a polarized magnetic orientation. The second substance is bound to the first substance and inhibits physical contact between the at least one atom and other atoms and molecules to thereby inhibit spin relaxation of the polarized magnetic orientation of the at least one atom.08-27-2009
20090214432Radicals and Their Use As Paramagnetic Agents in a DNP Process - The invention relates to new radicals, their use as paramagnetic agents in a method for the dynamic nuclear polarisation and a method for the dynamic nuclear polarisation of compounds comprising carboxyl groups.08-27-2009
20110150778Assembly of Gas-Filled Microvesicle With Active Component For Contrast Imaging - Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC comprises a targeting ligand a diagnostic agent or any combination thereof. Optionally a bioactive agent can further be associated to the MAC. The assembly of the invention can be formed from gas-filled microbubbles or microballoons and a MAC having preferably nanometric dimensions, e.g. a micelle, and is used as an active component in diagnostically and/or therapeutically active formulations, in particular for enhancing the imaging in the field of ultrasound contrast imaging, including targeted ultrasound imaging, ultrasound-mediated drug delivery and other imaging techniques such as molecular resonance imaging (MRI) or nuclear imaging.06-23-2011
20110027188Methods, Compositions and Devices for Treating Lesioned Sites Using Bioabsorbable Carriers - An implantable medical device is disclosed having a plurality of smaller particles contained in a plurality of larger particles and configured to be released from the larger particles when the device is implanted in a patient. The smaller particles and the larger particles are made of bioabsorbable metal, glass or ceramic. A substance can be associated with the smaller particles. The larger particles can be embedded within at least a portion of the device.02-03-2011
20100129292METHOD AND APPARATUS FOR NONINVASIVE QUANTITATIVE DETECTION OF FIBROSIS IN THE HEART - Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein.05-27-2010
20110150777Magnetic resonance tomography imaging - A medical magnetic resonance tomography apparatus and a contrast agent for magnetic resonance tomography imaging of cavities in a patient are provided. The contrast agent is formed from a highly viscous magnetic resonance contrast agent. The highly viscous magnetic resonance contrast agent includes a substance. A specific magnetic resonance contrast can be generated by the substance.06-23-2011
20120201758PROCESS FOR PRODUCING FOOD - A process for producing a food is disclosed. The food material is contacted with a degradative enzyme and any one or more of a thickener in a non-solvated state, microorganism which generates a viscous material, nutritious substance and seasoning according to need. Then, a pressure treatment is performed followed by cooking after softening the food material by the action of the degradative enzyme. The process may be carried out in a packaging material for vacuum packaging such that the food retains the shape, color, taste, and flavor of the food material and includes the degradative enzyme inside the vacuum packaging uniformly.08-09-2012
20100297023Lipid - The present invention provides a lipid of the formula (I) R11-25-2010
20110150779DYNAMIC NUCLEAR POLARIZATION ENHANCED NUCLEAR MAGNETIC RESONANCE OF WATER UNDER AMBIENT CONDITIONS - A method and apparatus are provided for treating hydrated material in a fluid that contains water in which a stable nitroxide is attached to the hydrated material. A dynamic nuclear polarization process (DNP) is conducted on the hydrated material whereby to hyperpolarize the water. A polarization cell contains the hydrated material to obtain hyperpolarized water free from the nitroxide. The dynamic nuclear polarization process is conducted using components comprising a tunable, solid state high power X-band driver and an X-band resonator for microwave transmission to the hydrated material. The components can also include a radio-frequency nuclear magnetic resonance probe, a permanent magnet formed to receive the hydrated material, a portable nuclear magnetic resonance spectrometer, and an electron spin resonance detector. The components can be sized to be portable, and include electrical input and output and a lap-size hard-case with access to the electrical input and output.06-23-2011
20090180963FORMULATIONS FOR USE IN MEDICAL AND DIAGNOSTIC PROCEDURES - The present invention relates to formulations for use in medical or diagnostic procedures comprising a stabilizing agent alone or in combination with an osmotic agent. In one embodiment, the stabilizing agent is a natural hydrocolloid, preferably locust bean gum, and the osmotic agent is a sugar-based compound, preferably mannitol. The present invention also relates to formulations and methods for distending an anatomic segment. The present invention further relates to formulations and methods for delineating an anatomic segment on a diagnostic image, for example. The formulations of the present invention are especially suitable for use with diagnostic imaging procedures including, but not limited to, magnetic resonance imaging (MR), computer assisted tomography (CT), and CT-PET (position emission tomography), as well as other medical and therapeutic uses.07-16-2009
20080279778POLYGLUTAMATE CONJUGATES AND POLYGLUTAMATE-AMINO ACID CONJUGATES HAVING A PLURALITY OF DRUGS - Various biodegradable polyglutamate conjugates comprising recurring units of the general formulae (I), (II), (III), (IV), (V), and/or (VI) are prepared. The polymers are conjugated with a plurality of drugs. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications.11-13-2008
20090311189TEMPERATURE-JUMP DYNAMIC NUCLEAR POLARIZATION - In one aspect, the present invention provides a method for enhancing the sensitivity of liquid-state NMR or MRI experiments. In general, the method involves providing a frozen sample in a magnetic field, wherein the frozen sample includes a polarizing agent with at least one unpaired electron and an analyte with at least one spin half nucleus; polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the at least one unpaired electron of the polarizing agent; melting the frozen sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the molten sample. In certain embodiments, the methods further comprise a step of freezing a sample in a magnetic field to provide the frozen sample in a magnetic field.12-17-2009
20080219932Magnetic resonance spectroscopy of breast biopsy to determine pathology, vascularization and nodal involvement - Robust classification methods analyse magnetic resonance spectroscopy (MRS) data (spectra) of fine needle aspirates taken from breast tumours. The resultant data when compared with the histopathology and clinical criteria provide computerized classification-based diagnosis and prognosis with a very high degree of accuracy and reliability. Diagnostic correlation performed between the spectra and standard synoptic pathology findings contain detail regarding the pathology (malignant versus benign), vascular invasion by the primary cancer and lymph node involvement of the excised axillary lymph nodes. The classification strategy consisted of three stages: pre-processing of MR magnitude spectra to identify optimal spectral regions, cross-validated Linear Discriminant Analysis, and classification aggregation via Computerised Consensus Diagnosis. Malignant tissue was distinguished from benign lesions with an overall accuracy of 93%. From the same spectrum, lymph node involvement was predicted with an accuracy of 95% and tumour vascularisation with an overall accuracy of 92%.09-11-2008
20110008261METHOD TO PRODUCE HYPERPOLARISED AMINO ACIDS AND AMINOSULPHONIC ACIDS - The invention relates to a dynamic nuclear polarisation (DNP) method for producing hyperpolarised amino acids and amino sulphonic acids and compositions for use in the method. As a sample, an ammonium salt of an amino acid, an ammonium salt of an aminosulphonic acid, a carboxylate salt of an amino acid, a sulphonate salt of an aminosulphonic acid or mixtures thereof is used.01-13-2011
20100226860NEUROMYELITIS OPTICA AUTOANTIBODIES AS A MARKER FOR NEOPLASIA - The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).09-09-2010
20110020236METHOD FOR THE SYNTHESIS OF HOLLOW SPHERES - The present invention relates to a method of synthesizing acoustically active biodegradable hollow spheres with a size below 1 micron. By using water soluble organic solvents and pegylated polymers, direct precipitation of these spheres is facilitated leading to a fast and convenient preparation route.01-27-2011
20100284928METHODS FOR IN VIVO ATHEROSCLEROTIC PLAQUE CHARACTERIZATION USING MAGNETIC SUSCEPTIBILITY TO IDENTIFY SYMPTOM-PRODUCING PLAQUES - Methods and uses of in vivo atherosclerotic plaque characterization in a subject in need thereof, that include detecting a level of one or more iron complexes in plaque in the subject, and comparing detected level to a known value determined from subjects without an atherosclerotic condition are disclosed.11-11-2010
20110135575METALLOPROTEIN MRI CONTRAST AGENTS AND RELATED METHODS - The present invention generally relates to Magnetic Resonance Imaging (MRI) analysis of the location, presence, and/or quantity of a particular molecule or material. In some embodiments, the invention relates to compositions and methods for determination of an analyte, wherein a compositions may produce an MRI signal that can be affected by the presence of a particular composition (e.g., analyte). In a particular embodiment, the composition comprises a protein. The invention also provides related nucleic acid molecules, polypeptides, and fragments thereof. Compositions of the invention may exhibit reduced toxicity and may be readily delivered in vivo. Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like.06-09-2011
20110008260Use of Nanocrystals for Drug Delivery from a Balloon - A drug delivery balloon (01-13-2011
20100322864TELEMETRY THROUGH REMOTE DETECTION OF NMR-ACTIVE PARTICLES - Various methods of telemetry for nuclear magnetic resonance applications are described. NMR-active particles are introduced into a system which is to undergo an NMR measurement. In various embodiments, the NMR-active particles have a resonance peak in a spectral region which is substantially free from any NMR signal originating from material native to the system. In some embodiments, the NMR-active particles are chemically functionalized to target a constituent within the system. In certain applications, changes in the detected resonance peak can be used to quantify certain characteristics about the system, e.g., a concentration of an analyte, whether a targeted constituent is present within the system.12-23-2010
20100178250Method of Local Delivery of Bioactive and Diagnostic Agents Using Magnetizable Bone Cement - A method of making a magnetizable implant, the method includes mixing a curable matrix and the at least one of the bioactive agent or the diagnostic agent associated with the magnetizable carrier to form a magnetizable curable matrix; implanting the magnetizable curable matrix in a cavity in a body of a mammal whereby the magnetizable curable matrix takes on a shape of the cavity and forms a molded magnetizable curable matrix; simultaneously curing the molded magnetizable curable matrix and applying the magnetic field and thereby causing the at least one of the bioactive agent or the diagnostic agent associated with a magnetizable carrier to move and arrange within the molded magnetizable curable matrix at or near an interface between the cavity and an outer surface of the molded magnetizable curable bioactive matrix.07-15-2010
20110097274Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters - This invention provides a compound having the structure:04-28-2011
20100158810Enhanced 13C NMR By Thermal Mixing With Hyperpolarized 129XE - A method of preparing a hydrogen-containing 06-24-2010
20100196281USE OF RESINIFERATOXIN (RTX) FOR PRODUCING AN AGENT FOR TREATING JOINT PAINS AND METHOD FOR APPLYING SAID AGENT - A method for treating a joint affected by pain that involves injecting an agent that includes resiniferatoxin (RTX) dissolved in a physiologically suitable solvent locally into the intracapsular region or the bursa of the joint affected by pain.08-05-2010
20120308484Clonal strains of attenuated vaccinia viruses and methods of use thereof - Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.12-06-2012
20090117051URIDINE DIETARY SUPPLEMENTATION COMPLIANCE METHODS AND USE THEREOF - This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source.05-07-2009
20090162288Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods - Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The combination can also be used as a preventive measure or as a treatment to reduce or eliminate symptoms associated with oncolytic viral therapy.06-25-2009
20110002853THE USE OF THE SPIN CROSSOVER COMPLEX [MX+(L2)HW]AN)Z AS A MAGNETIC RESONANCE IMAGING CONTRAST AGENT - A method for magnetic resonance imaging of a human or animal body includes providing a spin crossover complex having the general formula [M01-06-2011
20100080757METHOD OF DETECTING ABNORMAL TISSUE - A method for detecting abnormal biological tissue includes administering a vasoactive agent and determining the rate of blood flow in a tissue of interest.04-01-2010
20100322865DEUTERATED METABOLIC WATER PRECURSOR FOR DETECTING AND TREATING DISEASED TISSUE - A method of diagnosing a mitochondrial related disease in a subject includes administering a deuterated metabolic water precursor to the subject, measuring a rate of deuterated water formation in a sample region of the subject, and comparing the measured deuterated water formation in the sample region to a control value. A difference between the rate of deuterated water formation in the sample region compared to a control value is indicative of a mitochondrial related disease.12-23-2010
20090087381CHELATOR-FUNCTIONALIZED NANOPARTICLES - Provided herein are chelator-functionalized nanoparticles comprising a passive core; and an active coating that demonstrate T1 magnetic resonance pattern upon exposure to a magnetic field. Also provided are methods of making such chelator-functionalized nanoparticles as well as imaging methods using the nanoparticles.04-02-2009
20110064674LUMINESCENT MULTIMODAL NANOPARTICLE PROBE SYSTEM AND METHOD OF MANUFACTURE THEREOF - A method of manufacture of a luminescent nanoparticle probe system includes forming a bismuth sulfide core; and coating the bismuth sulfide core with a shell.03-17-2011
20110064673New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them - The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.03-17-2011
20120045397ULTRASONICALLY-TRIGGERED DRUG VEHICLE WITH MAGNETIC RESONANCE IMAGING FUNCTION - Present invention relates to an ultrasonically-triggered drug vehicle with magnetic resonance imaging function. In the delivery system of the invention, tracks the of drug vehicle carrying a certain drug (or drugs) is detectable by magnetic resonance imaging, and the release of drug is triggered by ultrasonication when the drug vehicle arrives at target site and accumulates to a desirable concentration. The MRI-guided drug delivery system provides improved accuracy of drug releasing, including position and timing.02-23-2012
20100247444COMPOUND, DIAGNOSTIC AGENT, NUCLEAR MAGNETIC RESONANCE ANALYSIS METHOD, NUCLEAR MAGNETIC RESONANCE IMAGING METHOD, MASS SPECTROMETRY METHOD AND MASS SPECTROMETRY IMAGING METHOD - To produce a labeled compound for a selected biological substance not using a radioisotope atom which has a risk of exposure to radioactivity and limitation on handling time but using a stable isotope atom; and that the labeled compound can be measured with good sensitivity separably from naturally occurring compounds of the selected biological substance which are substituted with the stable isotope atom. Choline as a biological substance is labeled by substituting the nitrogen atom of the quaternary ammonium group and all the carbon atoms of the methyl group attached to the nitrogen atom with respective isotopes 09-30-2010
20120064009METHODS OF LEUKEMIA CELL DETECTION - Methods are provided for, inter alia, determining the presence of leukemia cells in a subject, determining the change or potential change in the number of leukemia cells in the subject with time, determining whether a tissue in a subject contains a plurality of leukemia cells or a plurality progenitor leukemia cells, and determining whether a leukemia therapy administered to a subject is capable of decreasing the number of leukemia cells in a tissue of the subject.03-15-2012
20110085985NOVEL SUBSTITUTED AZABENZOXAZOLES - The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH;04-14-2011
20110091389PARTICLES WITH RADIATION ACTIVATED ADHESIVE - Techniques are generally described for particles with a surface including an adhesion material. The adhesion material may be selectively activated in response to radiation. The particles may be distributed proximate to a target through a fluid system. Radiation may be emitted toward the target causing the adhesion material to activate. The activated adhesive material on the surface of the particles may adhere to the target providing a fiducial mark or reference point. The fiducial mark may be visible through a medical imaging technique. In some examples, the particles may be nanoparticles. In some examples, the radiation may be infrared radiation.04-21-2011
20110104067METHODS FOR IN VIVO EVALUATION OF PULMONARY PHYSIOLOGY AND/OR FUNCTION USING NMR SIGNALS OF POLARIZED 129XE - In certain embodiments, methods of the present invention obtain dynamic data sets of an NMR spectroscopy signal of polarized 05-05-2011
20100290998Methods of preventing ischemic injury using peripheral nociceptive stimulation - Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits ischemia-related cardiac tissue damage. Methods of inhibiting cardiac tissue damage by topically administering the TRPV1 agonist, capsaicin are provided.11-18-2010
20100092391IMAGING AGENTS AND METHODS OF USE THEREOF - Compositions and methods useful in connection with magnetic resonance imaging are provided. Metabolites hyperpolarized by dynamic nuclear polarization are used as reporter molecules in nuclear magnetic resonance (“NMR”) spectroscopy to study metabolic pathways and diagnose disease states. The reporter molecules include hyperpolarized glutamine and hyperpolarized acetate. The invention includes the reporter molecules, compositions including the reporter molecules in pharmaceutically acceptable carriers, methods for studying metabolic pathways that include introducing one or more of the reporter molecules to a mammalian subject and imaging a target substance using NMR spectroscopy, and kits useful in studying metabolic pathways that incorporate one or more of the reporter molecules and instructions for their use.04-15-2010
20120121515METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants are described herein.05-17-2012
20120128594SELECTIVE INFARCTED-TISSUE-TARGETING BACTERIA AND USE THEREOF - The present invention relates to bacteria which specifically target infracted tissue and use thereof. The present invention provides a selective infracted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infracted tissue or in selectively imaging the infracted tissue. The infracted tissue-targeting bacterium of the present invention can finish treatments by using antibiotics, and therefore, have remarkable advantages as compared to gene therapy using recombinant viruses. The infracted tissue-targeting bacterium of the present invention have a significantly high affinity and specificity to infracted myocardium or infracted brain, thereby significantly reducing undesired transfections in the organs or tissues other than the heart. The gene expression by the infracted tissue-targeting bacterium of the present invention in infracted myocardium or infracted brain is remotely controllable.05-24-2012
20100209352SYNTHESIS AND CONJUGATION OF IRON OXIDE NANOPARTICLES TO ANTIBODIES FOR TARGETING SPECIFIC CELLS USING FLUORESCENCE AND MR IMAGING TECHNIQUES - The invention provides for methods for producing water-soluble iron oxide nanoparticles comprising encapsulating the nanoparticles in phospholipids micelles. Also provided are methods for conjugating the inventive nanoparticles via functionalized phospholipids to a target molecule, such as an antibody. The invention further provides methods for using the nanoparticle-antibody conjugate of the invention as a contrast agent to image specific cells or proteins in a subject using fluorescent and magnetic imaging techniques.08-19-2010
20110182822Biomarkers for Painful Intervertebral Discs and Methods of Use Thereof - The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc.07-28-2011
20110182821CLUSTERED MAGNETIC PARTICLES AS TRACERS FOR MAGNETIC PARTICLE IMAGING - The invention provides a magnetic tracer material for use in magnetic particle imaging and a manufacturing method thereof. The magnetic tracer material comprises clusters of a plurality of magnetic particles that are clustered in a controlled way to form individual entities, for example, stabilized oil droplets, solid emulsion particles, liposomes, polymersomes or vesicles, or naturally occurring biological entities such as cells or viruses.07-28-2011
20120219507METHOD OF DETERMINING METABOLIC FUNCTION - The present invention provides a novel lactate difference imaging (LDI) technique, allowing assessment of the metabolic responses of tissue over a period of time. This approach utilises lactate change over a time period as an indicator of viable tissue, and offers benefits in the management and treatment of the effects of many common diseases, in particular stroke.08-30-2012
20100172842ASSESSMENT OF BLOOD-BRAIN BARRIER DISRUPTION - A method of analyzing a blood-brain barrier of a subject is disclosed. A detectable dose of an MRI contrast agent is administered to the subject, and a plurality of magnetic resonance images of the subject's brain are acquired over a predetermined time-period. Two or more of the magnetic resonance images are compared thereamongst so as to determine variations in concentration of the contrast agent in the brain, and blood-brain barrier function is assessed based on the variations.07-08-2010
20100047178PERYLENEQUINONE DERIVATIVES AND USES THEREOF - The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.02-25-2010
20090060842METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATITIS - In a method for diagnosis and treatment of a patient with regard to prostatitis, a differential diagnosis of prostatitis versus prostate cancer and/or BPH is conducted on a patient using a cost-effective diagnosis method. Given diagnosed prostatitis, a cost-effective decision test is implemented on the patient to determine whether the patient exhibits complaints locally in the region of the prostate or in the rest of the body. A molecular inflammation marker is administered to the patient, wherein a cost-effective imaging method is implemented in the region of the prostate of the patient given local complaints or a cost-intensive imaging method is implemented on the entire patient given complaints in the rest of the body. An inflammation-inhibiting treatment is implemented in the body region of the patient that is detected as inflamed via the respective imaging method.03-05-2009
20120225020UNSATURATED CHOLINE ANALOGS AND CHEMICAL SYNTHESIS THEREOF - This disclosure provides choline analogs comprising the following structure:09-06-2012
20110038802METHOD OF DETERMINING ALANINE TRANSAMINASE (ALT) ACTIVITY BY 13C-MR DETECTION USING HYPERPOLARISED 13C-PYRUVATE - The invention relates to a method of determination of alanine transaminase (ALT) activity by 02-17-2011
20100166662MAGNETIC RESONANCE IMAGING METHOD USING VANADYL-BASED CONTRAST AGENTS - A new, clinically applicable magnetic resonance imaging (MRI) method has been developed for in vivo imaging of a population of cells in a subject based on a class of paramagnetic divalent vanadyl-based contrast agents. The method includes administering to a subject a V07-01-2010
20090162289Water soluble tetrapyrollic photosensitizers for photodynamic therapy - A tetrapyrollic photosensitizer compound having at least one pendant —CH06-25-2009
20100247445POLYMERIC DRUG CARRIER FOR IMAGE-GUIDED DELIVERY - Described are Chemical Exchange-dependent Saturation Transfer (CEST) contrast agents for Magnetic Resonance Imaging (MRI) comprising a polymersome provided with a paramagnetic agent. The polymersome preferably comprises a polymeric shell enclosing a cavity, wherein the cavity comprises a pool of proton analytes, and wherein the shell allows diffusion of the proton analytes. The polymersome-based CEST MRI contrast agents are suitable as drug carriers useful in MRI-guided drug release.09-30-2010
20120128593USE OF A MAGNETIC RESONANCE IMAGING MEDIUM COMPRISING HYPERPOLARIZED 13C PYRUVATE FOR THE DETECTION OF INFLAMMATION OR INFECTION - The invention relates to a method of 05-24-2012
20100233089IMAGING OF GENETIC MATERIAL WITH MAGNETIC RESONANCE - A method for imaging genetic material such as DNA, RNA and genes by magnetic resonance imaging incorporating hyperpolarization techniques, such as PASADENA or DNP may be used in various app metabolomics, medical diagnosis and genetic research.09-16-2010
20120087867Method for the Generation of Nuclear Hyper-Antipolarization in Solids Without the Use of High Magnetic Fields or Magnetic Resonant Excitation - A method of inducing nuclear spin hyper-antipolarization in a solid material is disclosed and described. The solid material can be subjected to an ultralow temperature and a magnetic field. The solid material can include donor nuclei and a carrier material while the material also has both a nuclear spin and an electron spin which are coupled sufficiently to allow an Overhauser effect. The solid material can be subjected at the ultralow temperature to a light source for a time sufficient to induce a substantial nuclear spin antipolarization in the solid material and form a nuclear spin hyper-antipolarized material. The ultralow temperature and light source are controlled so as to be sufficient to drive a non-equilibrium nuclear Overhauser effect of hyperfine coupled electron and nuclear spins. The resulting nuclear spin hyper-antipolarized material can be used for a variety of applications such as medical imaging and quantum computing. These materials can be readily formed relatively quickly and are generally stable at room temperatures.04-12-2012
20100034748Molecular imaging probes based on loaded reactive nano-scale latex - The present invention relates to a loaded reactive nanoscale latex particle synthesized from mixture of monomers containing water insoluble monomers, at least two ethylenically functionalities monomers, halo-aromatic-polyethyleneglycol-methacrylate, polyethyleneglycolacrylate containing macromonomers, and up to 10 wt % other ethylenic monomers different from above monomers. The reactive halo-aromatic groups on the surface of latex particle are servable as linkers to react with peptides, antibodies, nucleic acids, ligands or other biomolecules.02-11-2010
20090280063NOVEL PEI-PEG GRAFT COPOLYMER COATING OF IRON OXIDE NANOPARTICLES FOR INFLAMMATION IMAGING - A nanostructure includes a nanoparticle core (11-12-2009
20100202974NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.08-12-2010
20130017152METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.01-17-2013
20130017153UNIT DOSAGE OF APADENOSON - The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.01-17-2013
20130022548Methods and Compositions Relating to Reporter Gels for Use in MRI Techniques - The present invention describes methods and compositions for non-invasively assessing the molecular structure of biocompatible hydrogels using MRI analysis. It is shown that biocompatible hydrogels prepared from polymerizing macromolecules that are attached to a paramagnetic, superparamagnetic or ferromagnetic contrast agents form reporter gels wherein monitoring of the changes in the structure of the hydrogels by MRI is facilitated by the presence of such paramagnetic, superparamagnetic or ferromagnetic agents in the biocompatible hydrogel.01-24-2013
20080226561THERAPEUTIC USE OF ANTI-TF-ANTIGEN ANTIBODY - The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF—Ag, or for detection of tumors or metastatic foci which express TF—Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF—Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF—Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metastatic foci or tumors which comprise cancer cells expressing TF—Ag.09-18-2008
20080226560COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.09-18-2008
20080213185Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof - The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.09-04-2008
20130101516NANOPARTICLES AND NANOPARTICLE COMPOSITIONS - The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.04-25-2013
20080199401Method for Dissolution of Gases with Short-Lived Physical Properties in a Liquid - The invention relates to a process for dissolving a gas with short-lived physical properties in a liquid, comprising the steps of providing the gas with short-lived physical properties, providing the liquid and bringing the gas with short-lived with short-lived physical properties is fed into the liquid via a semi-permeable membrane that is permeable to gas.08-21-2008
20110243855METHOD AND IMAGING MEDIUM FOR USE IN THE METHOD - The invention relates to a method of 10-06-2011
20110250143PROCESS FOR PREPARING CHLORINS AND THEIR PHARMACEUTICAL USES - The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalities that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging.10-13-2011
20130149250HYPERPOLARIZED AGENTS FOR MRI CHARACTERIZATION OF REDOX SYSTEMS IN VIVO - The present invention provides a MRI probe of use in detecting and characterizing redox systems in vivo. Also provided are methods of using the probe in MR imaging experiments for diagnosis of disease in a subject, for drug discovery and for probing the redox states of biological systems in vitro.06-13-2013
20090263325METHOD AND APPARATUS FOR THE DISSOLUTION AND FILTRATION OF A HYPERPOLARIZED AGENT WITH A NEUTRAL DISSOLUTION MEDIA - Methods and apparatuses that facilitate dissolving a hyperpolarized agent within a polarizer and transporting it to a receiver is provided. The methods include delivering water to a hyperpolarized agent contained within a polarizer, forming a hyperpolarized aqueous solution, transporting the aqueous solution through a fluid path system out of the polarizer, filtering the aqueous solution through a partical size exclusion filter to a receiver, and modifying the pH of the filtered hyperpolarized aquous solution with a dissolution medium contained in the receiver. Also disclosed herein are apparatuses for dissolving a hyperpolarized agent comprising a vial for containing a hyperpolarized imaging agent therein, a dissolution fluid path, a delivery fluid path, a particle size exclusion filter, and a receiver connected to the particle size exclusion filter and positioned to receive the filtered aqueous solution of the hyperpolarized imaging agent.10-22-2009
20130183245METHODS OF TREATING CEREBRAL AMYLOID ANGIOPATHY - Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.07-18-2013
20130183246SYSTEMS AND METHODS FOR HIGH-THROUGHPUT MICROFLUIDIC BEAD PRODUCTION - A system for producing microbeads includes a microfluidic device defining a supply channel and a shearing channel, a microbead precursor material disposed in the supply channel, a carrier fluid disposed in the shearing channel, and a pressure distribution system fluidly connected to each of the supply channel and the shearing channel to control at least relative pressures of the microbead precursor material and the carrier fluid. The supply channel includes a check valve adapted to be subjected to a bias pressure that is sufficient to close the check valve to flow of microbead precursor material when a supply pressure of the microbead precursor material is below a threshold pressure and is open to flow of the microbead precursor material when the supply pressure of the microbead precursor material is greater than the threshold pressure. An end of the supply channel opens into the shearing channel such that the microbead precursor material is sheared into droplets by the carrier fluid flowing through the shearing channel. A pressure of the carrier fluid is less than the bias pressure. The microbead precursor material and the carrier fluid are substantially immiscible.07-18-2013
20110311455ENCAPSULATED AGENT GUIDED IMAGING AND THERAPIES - A nano-capsule construct for imaging and therapeutic uses and method for production are provided. One nano-probe embodiment based on genome-depleted plant brome mosaic virus (BMV) whose interior is doped with indocyanine green (ICG), an FDA-approved near infrared fluorescent dye, is used to illustrate the invention. The material encapsulated in viral shell components may be coated with functionalized coatings such as branched, dendritic polymer coatings to improve longevity and distribution in the body as well as antibody conjugation for increased target specificity. The constructs can also be coated with ferromagnetic iron oxide nanoparticles, enabling the ICG-containing capsules to be used as nano-probes with the capability of being detected in both optical and magnetic resonance imaging. The capsules may be produced by purifying a plant or animal viruses and disassembling the viruses to provide virus shell components. The virus shell components are reassembled in the presence of a material for encapsulation thereby encapsulating said material within the core of the construct in one embodiment.12-22-2011
20090280064TRANSDERMAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL, DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS - A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to the skin of an animal or human. The application may be accomplished using biological cargo-laden nanoparticles in a device attachable to the skin. The device may be attached directly to the skin by a device containing a vasodilating agent or agents, or micro needles, or multi-layer time release material. The biological cargo-laden nanoparticles may comprise drugs, vaccines, bio-pharmaceuticals, imaging contrast agents, multimodal imaging contrast agents, biomolecules, or anti-infectives. The device may include a first plurality of different types of biological cargo-laden nanoparticles located in a corresponding second plurality of separate time release layers.11-12-2009
20130189187NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.07-25-2013
20120027686HK1-BINDING PROTEINS - The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.02-02-2012
20120294806DRUG CARRIER WITH THERMAL SENSITIVITY, MANUFACTURING METHOD THEREOF, AND USE THEREOF - A drug carrier with thermal sensitivity, a manufacturing method thereof, and a use thereof are disclosed. The drug carrier comprises a nano-magnetic particle, a drug, a composite polymer, and a dense silica shell. The nano-magnetic particle and the drug are encapsulated in the composite polymer which is formed by self-assembly a water-soluble polymer (such as poly vinyl alcohol) and a thermosensitive copolymer (such as Pluronic F68 or Pluronic F127). The stability and drug release of the drug carrier a can be adjusted by combining PVA and thermosensitive copolymer with a different ratio. When an external magnetic field was applied, the cores exhibit significant size shrinkage and the diameter of the drug carrier decreases more than 10 folds due to the change of temperature, which causes burst-like drug release because of shell destruction and physical collapse of the drug carrier.11-22-2012
20080279776Photosensitizers and MRI Enhancers - The present invention relates to the use of a compound of formula 3 or a salt thereof for the manufacture of a medicament or phototherapeutic agent for the treatment of acne, Aids, viral hepatitis, diabetic retinopathy, infection with sars virus, coronary artery stenosis, carotid artery stenosis, intermittent claudication, Asian (chicken) flu virus, cervical dysplasia or cancer of the blood, cervix, naso-pharynx, trachea, larynx, bronchi, bronchioles, bladder, esophagus, stomach, rectum, colon, prostate, hollow organs, bile duct, ureter, kidney, uterus, vaginal or other female adnexa. The invention also relates to methods of treating these diseases.11-13-2008
20120076733POST-BIOPSY CAVITY TREATMENT IMPLANTS AND METHODS - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.03-29-2012

Patent applications in class Magnetic imaging agent (e.g., NMR, MRI, MRS, etc.)

Patent applications in all subclasses Magnetic imaging agent (e.g., NMR, MRI, MRS, etc.)